Fig. 4From: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerHypothesized influence of treatment history on co-occurrence of mutated PIK3CA and HER2 overexpression. HER human epidermal growth factor receptor, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, T-DM1 trastuzumab emtansineBack to article page